Table 3.
Clinical characteristics | Number (Percentile) |
---|---|
Age (Mean/Median, y) | 49.5 ± 16.3/49.0 (20–85) |
Time of follow-up (Mean/Median, y) | 4.7/3.0 (0.08–20.50) |
Elevated LDH (N = 20) | 12 (60%) |
Ann Arbor Stage | |
IE | 73 (64.6%) |
IIE | 25 (22.1%) |
IIIE | 4 (3.5%) |
IVE | 11 (9.7%) |
Cancer-directed surgery (CDS) | 31 (27.4%) |
Chemotherapy/Radiotherapy details | |
No chemotherapy or radiotherapy | 6 (5.3%) |
Chemotherapy alone | 57 (50.4%) |
CHOP | 17 |
CHOP + CDS | 9 |
R-CHOP | 13 |
R-CHOP + CDS | 7 |
Radiotherapy alone | 13 (11.5%) |
Radiotherapy + chemotherapy | 37 (32.7%) |
Radiotherapy + CHOP | 16 |
Radiotherapy + CHOP + CDS | 1 |
Radiotherapy + R-CHOP | 13 |
Radiotherapy + R-CHOP + CDS | 1 |
Clinical outcomes | |
No evidence of disease | 93 (82.3%) |
Alive with disease | 6 (5.3%) |
Die of the disease | 11 (9.7%) |
Die of the other disease | 3 (2.7%) |
Abbreviations: LDH lactate dehydrogenase, DLBCL diffuse large B-cell lymphoma, (R)-CHOP (Rituximab)-cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone